Article (Scientific journals)
Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Baron, Frédéric; Labopin, Myriam; Peniket, Andy et al.
2015In Cancer, 121, p. 1048-1055
Peer Reviewed verified by ORBi
 

Files


Full Text
2015_Baron_EBMT_ALWP_AML_RIC_FBvsFM_Cancer.pdf
Publisher postprint (269.17 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
acute myeloid leukemia (AML); busulfan; fludarabine; graft-versus-host disease (GVHD); melphalan; reduced-intensity conditioning (RIC); transplantation
Abstract :
[en] BACKGROUND: Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) are 2 widely used reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (allo-SCT). METHODS: The current survey compared transplantation outcomes for a cohort of 394 acute myeloid leukemia (AML) patients given bone marrow or peripheral blood stem cells from human leukocyte antigen–identical siblings after FB (n5218) or FM (n5176). Patients given manipulated grafts and those given Tcell–depleting agents (anti-thymocyte globulins or alemtuzumab) were not included. RESULTS: At the time of transplantation, 266 patients (68%) were experiencing their first complete remission (CR), 69 (18%) were experiencing a later CR, and 59 (15%) had advanced disease. The incidences of acute and chronic graft-versus-host disease were similar in the 2 groups of patients. The 2-year relapse incidence (RI), nonrelapse mortality (NRM) rate, leukemia-free survival (LFS) rate, and overall survival (OS) rate were 31%63%, 18%63%, 51%64%, and 54%64%, respectively, for FB patients and 20%63% (P5.007), 20%63% (P5.4), 60%64% (P5.08), and 62%64% (P5.2), respectively, for FM patients. Among FB patients given intravenous busulfan (n581), the 2-year RI, NRM, LFS, and OS rates were 26%65% (P5.43 vs FM patients), 25%66% (P5.18), 49%67% (P5.07), and 54%67% (P5.13), respectively. In multivariate analyses, FM was associated with a lower RI (hazard ratio [HR], 0.5; P5.01) and a trend toward higher NRM (HR, 1.6; P5.1) with similar LFS (HR, 0.8; P5.2) and OS (HR, 0.9; P5.6). CONCLUSIONS: These results suggest that although FM provides better AML control than FB as an RIC regimen for allo-SCT, the 2 regimens provide similar survival. Multicenter randomized studies are needed to confirm these findings.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric  ;  Université de Liège - ULiège > GIGA-R : Hématologie
Labopin, Myriam
Peniket, Andy
Jindra, Pavel
Afanasyev, Boris
Sanz, Miguel
Deconinck, Eric
Nagler, Arnon
Mohty, Mohamad
Language :
English
Title :
Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Publication date :
2015
Journal title :
Cancer
ISSN :
0008-543X
eISSN :
1097-0142
Publisher :
Wiley, Hoboken, United States - New Jersey
Volume :
121
Pages :
1048-1055
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 11 December 2014

Statistics


Number of views
92 (2 by ULiège)
Number of downloads
420 (1 by ULiège)

Scopus citations®
 
71
Scopus citations®
without self-citations
55
OpenCitations
 
61

Bibliography


Similar publications



Contact ORBi